Glaucoma, Open-Angle Clinical Trial
Official title:
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
Verified date | May 2019 |
Source | Afyon Kocatepe University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Glaucoma is one of the leading causes of blindness worldwide that is a chronic public health problem. Unfortunately, glaucoma can be diagnosed when the disease reaches a certain level in today's conditions. The aim of this study was to investigate the diagnostic methods that can diagnose glaucoma before it reaches the advanced level and to identify pathophysiological processes. In this study, choroidal thickness was investigated in primary open-angle glaucoma cases and its correlations with OCT and multifocal ERG parameters were evaluated.
Status | Completed |
Enrollment | 96 |
Est. completion date | April 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria for the glaucoma group: - the best corrected visual acuity (BCVA) of 0.6 and above - Intraocular pressure being above 21 mmHg - Detection of open-angle by gonioscopy - Detection of glaucomatous optic disc pitting by fundus examination - Visual field defect in perimetry (Carl Zeiss Meditec AG, Germany) Exclusion Criteria for the glaucoma group: - A secondary cause of glaucoma - Angle-closure in gonioscopic examination - Corneal opacity or cataract at the level that may affect imaging, vitreous pathology - Intravitreal hemorrhage that may affect fundus appearance, retinal pathology - Chorioretinopathy, optic neuropathy, optic disc pathology, spherical refractive error of 6D and above, cylindrical refraction error of 3D and above and systemic diseases which may affect ocular blood flow Inclusion Criteria for the healthy group: - The best corrected visual acuity (BCVA) of 0.8 and above Exclusion Criteria for the healthy group: - Presence of systemic disease that may affect choroid blood flow - Ocular conditions that may affect test measurements |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Afyon Kocatepe University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Macular choroidal thickness measure | Measuring macular choroidal thickness at baseline, at 1-month, at 3-month and at 6-month by using optical coherence tomography | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in multifocal electroretinography parameters (Amplitudes [nv/deg2] and impulse times [ms] of N1, N2 and P1 waves in Ring-1, Ring-2, Ring-3 and Ring-4) | Comparison of the mean multifocal electroretinography parameters (Amplitudes [nv/deg2] and impulse times [ms] of N1, N2 and P1 waves in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in amplitudes of N1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [nv/deg2] | Comparison of the mean amplitudes of N1 wave [nv/deg2] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in amplitudes of N2 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [nv/deg2] | Comparison of the mean amplitudes of N2 wave [nv/deg2] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in amplitudes of P1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [nv/deg2] | Comparison of the mean amplitudes of P1 wave [nv/deg2] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in impulse times of N1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [ms] | Comparison of the mean impulse times of N1 wave [ms] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in impulse times of P1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [ms] | Comparison of the mean impulse times of P1 wave [ms] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in P1/N1 ratio of N2 wave in Ring-1, Ring-2, Ring-3 and Ring-4 | Comparison of the mean P1/N1 ratios of N2 wave in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in the mean optic nerve head optical coherence tomography parameters (Retinal nerve fiber layer thickness [micrometers], disc area [mm2], cup-to-disc ratios, cup volume [mm3], neuroretinal rim area [mm2]) | Measuring optic nerve head optical coherence tomography parameters (Retinal nerve fiber layer thickness [micrometers], disc area [mm2], cup-to-disc ratios, cup volume [mm3], neuroretinal rim area [mm2]) at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in the mean neuroretinal rim area [mm2]) | Measuring neuroretinal rim area [mm2] at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in the mean cup volume [mm3] | Measuring cup volume [mm3] at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in the mean cup-to-disc ratios | Measuring cup-to-disc ratios at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in the mean disc area [mm2] | Measuring disc area [mm2] at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Primary | Changes in the mean retinal nerve fiber layer thickness [micrometers] | Measuring retinal nerve fiber layer thicknesses [micrometers] at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Secondary | Best-corrected visual acuity measure | Comparison of the mean best-corrected visual acuities at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Secondary | Intraocular pressure measure | Measuring intraocular pressure at 1-month, at 3-month and at 6-month | Baseline, 1-month, 3-month, 6-month | |
Secondary | Correlations between choroidal thickness and other parameters | Analyze correlations between changes of choroidal thicknesses and changes of other parameters during the study. | Baseline, 6-month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05044793 -
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
|
||
Recruiting |
NCT06201455 -
Evaluation of Phacogoniotomy in Medically-controlled POAG
|
N/A | |
Recruiting |
NCT03369886 -
The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI
|
N/A | |
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Recruiting |
NCT02679482 -
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
Completed |
NCT00693485 -
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
|
Phase 2 | |
Completed |
NCT00753168 -
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
|
Phase 1/Phase 2 | |
Completed |
NCT00051194 -
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
|
Phase 2 | |
Recruiting |
NCT04920227 -
Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma
|
N/A | |
Active, not recruiting |
NCT03868124 -
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
|
Phase 3 | |
Completed |
NCT03267862 -
Scleral Response to Intraocular Pressure (IOP)
|
N/A | |
Recruiting |
NCT06066645 -
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
|
Phase 3 | |
Recruiting |
NCT04912362 -
The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04949802 -
Glaucoma Surgery Using the ViaLase Laser System
|
N/A | |
Recruiting |
NCT04038034 -
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04632329 -
Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
|
N/A | |
Completed |
NCT01215786 -
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
|
Phase 1 |